ABAylin Berwanger

Aylin Berwanger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aylin Berwanger has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Toward Anti‐Herpesviral PROTACs: Assessing the Challenges for Targeted Protein Degradation on the Example of Kaposi's Sarcoma‐Associated Herpesvirus Latency‐Associated Nuclear Antigen

    by Aylin Berwanger, Saskia Catherina Stein, Sarah Brandner, Andreas Martin Kany, Sebastian Heinz, Brigitta Loretz, Claus‐Michael Lehr, Anna Katharina Herta Hirsch, Frederik Lermyte, Thomas Friedrich Schulz, et al.

    Kaposi's sarcoma‐associated herpesvirus (KSHV) is a gamma‐herpesvirus linked to several malignancies, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Among its numerous encoded proteins, the latency‐associated nuclear antigen (LANA) plays a pivotal role in the maintenance of viral latency and oncogenesis. This manuscript focuses on therapeutic strategies aimed at targeting LANA to prevent KSHV‐associated diseases. Following the concept of proteolysis‐targeting chimeras (PROTACs), heterobifunctional compounds are designed and synthesized, which are able to bind LANA as well as specific E3 ligases. To achieve induction of targeted protein degradation, formation of functional ternary complexes as well as uptake into cells is required, which necessitates optimization of multiple compound parameters in parallel. Hence, the conjugates are tested using an assay pipeline tailored for PROTAC drug discovery by checking properties such as binding affinities, formation of ternary complexes, and in vitro absorption, distribution, metabolism, excretion (ADME) data. Restricted permeation as the reason for lack of intracellular target degradation is especially identified.


  • Open Access

    Disrupting Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) Latent Replication with a Small Molecule Inhibitor

    by Aylin Berwanger, Saskia C. Stein, Andreas M. Kany, Melissa Gartner, Brigitta Loretz, Claus-Michael Lehr, Anna K. H. Hirsch, Thomas F. Schulz, Martin Empting

    Kaposi's sarcoma-associated herpesvirus (KSHV) can establish latent lifelong infections in infected individuals. During viral latency, the latency-associated nuclear antigen (LANA) mediates the replication of the latent viral genome in dividing cells and tethers them to mitotic chromosomes, thus ensuring their partitioning into daughter cells during mitosis. This study aims to inhibit Kaposi's sarcoma-associated herpesvirus (KSHV) latent replication by targeting the LANA-DNA interaction using small molecular entities. Drawing from first-generation inhibitors and using growth vectors identified through STD-NMR, we expanded these compounds using Suzuki-Miyaura cross-coupling. This led to a deeper understanding of SAR achieved by microscale thermophoresis (MST) measurements and cell-free tests via electrophoretic mobility shift assays (EMSA). Our most potent compounds successfully inhibit LANA-mediated replication in cell-based assays and demonstrate favorable in vitro ADMET-profiles, including suitable metabolic stability, Caco-2 permeability, and cytotoxicity. These compounds could serve as qualified leads for the future refinement of small molecule inhibitors of KSHV latent replication.


  • KSHV-Specific Antivirals Targeting the Protein–DNA Interaction of the Latency-Associated Nuclear Antigen

    by Aylin Berwanger, Martin Empting

    The Kaposi sarcoma-associated herpesvirus (KSHV) is an oncogenic human herpesviruses that is responsible for cancer, especially in immunosuppressed people, such as patients with AIDS. So far, there...


  • Open Access

    A New PqsR Inverse Agonist Potentiates Tobramycin Efficacy to Eradicate Pseudomonas aeruginosa Biofilms

    by Christian Schütz, Duy‐Khiet Ho, Mostafa Mohamed Hamed, Ahmed Saad Abdelsamie, Teresa Röhrig, Christian Herr, Andreas Martin Kany, Katharina Rox, Stefan Schmelz, Lorenz Siebenbürger, et al.

    Pseudomonas aeruginosa (PA) infections can be notoriously difficult to treat and are often accompanied by the development of antimicrobial resistance (AMR). Quorum sensing inhibitors (QSI) acting on PqsR (MvfR) – a crucial transcriptional regulator serving major functions in PA virulence – can enhance antibiotic efficacy and eventually prevent the AMR. An integrated drug discovery campaign including design, medicinal chemistry‐driven hit‐to‐lead optimization and in‐depth biological profiling of a new QSI generation is reported. The QSI possess excellent activity in inhibiting pyocyanin production and PqsR reporter‐gene with IC50 values as low as 200 and 11 × 10−9 m, respectively. Drug metabolism and pharmacokinetics (DMPK) as well as safety pharmacology studies especially highlight the promising translational properties of the lead QSI for pulmonary applications. Moreover, target engagement of the lead QSI is shown in a PA mucoid lung infection mouse model. Beyond that, a significant synergistic effect of a QSI‐tobramycin (Tob) combination against PA biofilms using a tailor‐made squalene‐derived nanoparticle (NP) formulation, which enhance the minimum biofilm eradicating concentration (MBEC) of Tob more than 32‐fold is demonstrated. The novel lead QSI and the accompanying NP formulation highlight the potential of adjunctive pathoblocker‐mediated therapy against PA infections opening up avenues for preclinical development.